TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03872271

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ileal pouch-anal anastomosis with diverting loop ileastomy
Description: Defunctioning ileostomy has demonstrated its benefits (rate and seriousness of anastomotic leakage) in cancer for low colorectal and coloanal anastomoses, whereas there are no such good quality evidences in case of ileal pouch-anal anastomosis (IPAA) performed for inflammatory bowel disease (IBD). However, most surgical teams do protect systematically IPAA by an ileostomy.
Study: NCT02585258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 1 capsule containing a tablet of 5 mg prednisolone/ day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule containing a placebo tablet / day
Study: NCT02269202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam, tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam, tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crobenetine, i.v. infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04082975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1203
Description: Oral dose for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-1203-R
Description: Oral dose for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-1203 placebo
Description: Oral dose for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1203-R placebo
Description: Oral dose for 7 days
Study: NCT01703741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Gel (FE 999093)
Study: NCT03417622

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bracketing
Description: At the beginning of therapy, ultrasonographic examination is used to measure the tumor in three dimensions and bracket the tumor using 4-6 metal clips which will serve as markers for the initial tumor extent in case of tumor shrinkage in response to systemic treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bracketing
Description: At the beginning of therapy, ultrasonographic examination is used to measure the tumor in three dimensions and bracket the tumor using 4-6 metal clips which will serve as markers for the initial tumor extent in case of tumor shrinkage in response to systemic treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Description: All patients will receive primary systemic therapy according to the current institutional guidelines. Drugs include cytotoxic chemotherapy, hormonal therapy and/or anti-HER2/neu therapy as indicated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant therapy
Description: All patients will receive primary systemic therapy according to the current institutional guidelines. Drugs include cytotoxic chemotherapy, hormonal therapy and/or anti-HER2/neu therapy as indicated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-treatment volume margin resection
Description: The lumpectomy resection margin is planned according to the identifiable tumor at operation. The initial extent of the tumor at diagnosis is not taken in account. If there is complete clinical response to systemic therapy (i.e. no identifiable tumor), the center of the bracketed tissue is biopsied.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-treatment volume margin resection
Description: The lumpectomy includes the whole bracketed tissue to take in account the initial tumor extent before systemic therapy.
Study: NCT01900873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Strength Training
Description: IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The intervention group (strength IMT) will perform two daily sessions of 30 breaths. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain at least 40-50% of the actual Pi,max values. Each week, one training session will be performed under supervision. Training load will be increased during this session.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inspiratory Muscle Endurance Training
Description: IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The sham group (endurance IMT) will perform three daily sessions of 30 breaths and will train at a constant inspiratory load of no more than 10% of their initial Pi,max. Each week, one training session will be performed under supervision.
Study: NCT01139255

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Podcasting + mobile media
Description: Use of a weight loss podcast designed with health behavior theory

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Podcasting + mobile media
Description: Use of a weight loss podcast designed with health behavior theory
Study: NCT03242122

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHO Control 1 and 2 Glucose
Description: mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHO Control 1 and 2 Glucose
Description: mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHO Experimental 1 Slowly Digested
Description: mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHO Experimental 2 Digestion Resistant
Description: mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHO Experimental 3 Low Sugar
Description: mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHO Experimental 4 Maltodextrin
Description: mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
Study: NCT01675908

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stent Dysfunction
Description: Rate of stent dysfunction (%) which includes persistent hyperbilirubinemia or cholangitis that warrant stent exchange by another ERCP.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stent Dysfunction
Description: Rate of stent dysfunction (%) which includes persistent hyperbilirubinemia or cholangitis that warrant stent exchange by another ERCP.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complications
Description: Rates of procedural complications (%) such as pancreatitis, perforation or hemorrhage during stent placement will be assessed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complications
Description: Rates of procedural complications (%) such as pancreatitis, perforation or hemorrhage during stent placement will be assessed.
Study: NCT04155697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Chlorohexidine Gluconate soap
Description: Participants will wash hands for 30 seconds with 2% Chlorohexidine Gluconate soap.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 62% ethyl alcohol-based hand sanitizer
Description: Participants will apply 62% ethyl alcohol-based hand sanitizer for 30 seconds
Study: NCT03415971

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EMG in a month after termination of treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EMG in a month after termination of treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EMG in a 3 months after termination of treatment
Study: NCT02984683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR566658 (ACT14884)
Description: Pharmaceutical form:Solution Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR566658 (ACT14884)
Description: Pharmaceutical form:Solution Route of administration: Intravenous
Study: NCT01000584

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Arepanrix, Vaxigrip 2009/2010
Description: Group A: Single dose of Arepanrix and single dose of Vaxigrip 2009/2010 given concurrently
Study: NCT00040859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study: NCT00337805

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pentaspan
Description: When fluids are indicated either pentaspan or saline are given in a double blind randomized assignment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pentaspan
Description: When fluids are indicated either pentaspan or saline are given in a double blind randomized assignment
Study: NCT01433900

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tafluprost
Description: 1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
Study: NCT03415971

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EMG in a 3 months after termination of treatment
Study: NCT01433900

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: 1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
Study: NCT04115449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Injection dexmedetomidine 1 mcg /kg will be infused over a period of ten minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Normal Saline as a placebo will be infused over a period of ten minutes
Study: NCT01000584

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Arepanrix, Vaxigrip 2009/2010
Description: Group B: Single dose of Vaxigrip 2009/2010 given 3 weeks after single dose of Arepanrix
Study: NCT03052478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib 150 mg
Description: Vismodegib 150 mg will be administered orally once a day for 21 days as one cycle.
Study: NCT00427648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alkalinized xylocaine
Description: 30 cc of 1% xylocaine and 10 cc of 0.9% sodium bicarbonate, dosed twice a week for three weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: normal saline
Study: NCT02091089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755nm Alexandrite laser
Description: 755nm Alexandrite laser for the treatment of wrinkles
Study: NCT04362176

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pathogen reduced SARS-CoV-2 convalescent plasma
Description: Convalescent COVID-19 donor plasma is the liquid part of blood that is collected from patients who have recovered from COVID-19 infection. This plasma contains SARS-CoV-2 specific antibodies that may help fight the infection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactated Ringer's solution with multivitamins
Study: NCT01078376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil (TAK-491)
Description: Azilsartan medoxomil 80 mg, tablets, orally, one day only
Study: NCT00633152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftaroline
Description: 600 mg injected every 12 hours for at least 5 but not more than 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linezolid
Description: 600 mg parenteral infused over 60 minutes for a minimum of 5 days and a maximum of 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aztreonam
Description: 1000 mg infused over 60 minutes every 24 hours may be started with linezolid or added later (up to 72 hours after the first dose of linezolid) for subjects with a gram-negative infection indicated.
Study: NCT00401882

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Epinephrine (1 mg) IV additional doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Metoprolol 5 mg IV (up to two times only) instead of epinephrine additional doses
Study: NCT01998685

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanyl
Study: NCT01078376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil (TAK-491)
Description: Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil (TAK-491)
Description: Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil (TAK-491)
Description: Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only
Study: NCT00607789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 30 mg/day - 120 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical to study drug
Study: NCT01998685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Study: NCT05001490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone application based reminder
Description: Brushing reminders were given to the patients in experimental group through a smartphone application twice daily
Study: NCT04275219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tongfu capsules
Description: Tongfu capsules include 5 herbals

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The Placebo of Tongfu capsules
Description: The Placebo of Tongfu capsules are made from dextrin, starch and so on.
Study: NCT01643083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Rifaximin 400mg tid for 2 wk

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 2 week
Study: NCT03779399

Intervention type: OTHER
Intervention: Assessment of percentage of Treg, Th17, NKT and serum level of HE4, CA125 and ROMA.
Description: Treg, Th17, NKT cells in peripheral blood and ovarian tissue and serum level of HE4, CA125 and ROMA.

Intervention type: OTHER
Intervention: Assessment of percentage of Treg, Th17, NKT and serum level of HE4, CA125 and ROMA.
Description: Treg, Th17, NKT cells in peripheral blood and ovarian tissue and serum level of HE4, CA125 and ROMA.

Intervention type: OTHER
Intervention: Assessment of percentage of Treg, Th17, NKT and serum level of HE4, CA125 and ROMA.
Description: Treg, Th17, NKT cells in peripheral blood and ovarian tissue and serum level of HE4, CA125 and ROMA.

Intervention type: OTHER
Intervention: Assessment of percentage of Treg, Th17, NKT and serum level of HE4, CA125 and ROMA.
Description: Treg, Th17, NKT cells in peripheral blood and ovarian tissue and serum level of HE4, CA125 and ROMA.
Study: NCT02152787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of propofol 1.0mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol 0.5mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Study: NCT00670878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 x FEC 3 x DOC / Gemcitabine
Description: 3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicin 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 75 mg/m² body surface area i.v. (D), and Gemcitabine 1000 mg/m² i.v. (30 min infusion) (G), administered on day 1, followed by Gemcitabine 1000 mg/m² i.v. (30 min infusion) on day 8, repeated on day 22

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 x FEC 3 x DOC
Description: 3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicin 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 100 mg/m² body surface area i.v. (D), administered on day 1, repeated on day 22
Study: NCT01428024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Lip Volume
Description: Treatment of up to 1,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Lip Refresh
Description: Treatment of up to 0,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.
Study: NCT04511351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: chidamide administration during radiation and chemotherapy phase in the study group
Study: NCT02038634

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone
Study: NCT04786431

Intervention type: OTHER
Intervention: Blood collection for lipid profiling by LC-MS
Description: Blood withdrawal
Study: NCT02038634

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound guided injection using GE Healthcare LOGIQ e Ultrasound
Study: NCT02689895

Intervention type: OTHER
Group type: OTHER
Intervention: modified directly administered anti-retroviral therapy (mDAART)
Description: As described before
Study: NCT01017679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib 500mg/Gefitinib 250mg
Description: Gefitinib 500mg or 250mg is Taken Orally everyday by Experimental and controlled Arms respectively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib 500mg/Gefitinib 250mg
Description: Gefitinib 500mg or 250mg is Taken Orally everyday by Experimental and controlled Arms respectively
Study: NCT01252199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cαStx1/cαStx2
Description: cαStx1/cαStx2 administered concomitantly at a dose of 1 mg/kg (low dose cohort) or 3 mg/kg (high dose cohort)per antibody over 1 hour + standard of care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered over 1 hour + standard of care
Study: NCT01854372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-HCVAD and R-MC
Study: NCT00149071

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: 15 treatments of rTMS active with a duration of 30 minutes each
Study: NCT01527539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Dose individually adjusted. Injected twice daily immediately before breakfast and dinner. Administrated subcutaneously (s.c., under the skin)
Study: NCT04689958

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Gabapentin, pregabalin, or amitriptyline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: Gabapentin, pregabalin, or amitriptyline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D 5,000IU Oral Tablet
Description: Vitamin D 5000 IU oral tablet once daily
Study: NCT02265952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1500 250 mg SC/15 mg/kg IV/450 mg SC
Description: Participants received single dose of REGN1500 subcutaneous (SC) injection of 250 milligrams (mg) at Week 0 (Day 1), followed by single dose of REGN1500 intravenous (IV) injection of 15 milligrams per kilogram (mg/kg) at Week 2 (Day 15) and then followed by 4 doses of REGN1500 SC injection of 450 mg once weekly starting from Week 12 (Day 85). Only the first 2 enrolled participants received 4 weekly REGN1500 450 mg SC doses at weeks 12, 13, 14, and 15 per the protocol. This dose regimen was removed under protocol amendment 4. Participants were followed for a period of 24 weeks (through Week 26 \[Day 183\]) after the last dose of study drug in the main study period.
Study: NCT03459326

Intervention type: OTHER
Intervention: IIEF (International Index of Erectile Function questionnaire )
Description: The questionnaire is presented and answered without help. Answers to the IIEF Questionnaire will be collected in order to obtain the following scores (the total score is of no interest):~* Erectile function (score 1 to 30)~* Orgasmic function (score 0 to 10)~* Desire (score 2 to 10)~* Sexual satisfaction (score 0 to 15)~* Overall satisfaction (score 2 to 10)

Intervention type: OTHER
Intervention: IIEF (International Index of Erectile Function questionnaire )
Description: The questionnaire is presented and answered without help. Answers to the IIEF Questionnaire will be collected in order to obtain the following scores (the total score is of no interest):~* Erectile function (score 1 to 30)~* Orgasmic function (score 0 to 10)~* Desire (score 2 to 10)~* Sexual satisfaction (score 0 to 15)~* Overall satisfaction (score 2 to 10)

Intervention type: OTHER
Intervention: IIEF (International Index of Erectile Function questionnaire )
Description: The questionnaire is presented and answered without help. Answers to the IIEF Questionnaire will be collected in order to obtain the following scores (the total score is of no interest):~* Erectile function (score 1 to 30)~* Orgasmic function (score 0 to 10)~* Desire (score 2 to 10)~* Sexual satisfaction (score 0 to 15)~* Overall satisfaction (score 2 to 10)

Intervention type: OTHER
Intervention: IIEF (International Index of Erectile Function questionnaire )
Description: The questionnaire is presented and answered without help. Answers to the IIEF Questionnaire will be collected in order to obtain the following scores (the total score is of no interest):~* Erectile function (score 1 to 30)~* Orgasmic function (score 0 to 10)~* Desire (score 2 to 10)~* Sexual satisfaction (score 0 to 15)~* Overall satisfaction (score 2 to 10)
Study: NCT02960074

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Capsule
Description: We will treat patients with oral encapsulated frozen FMT over 2 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Capsule
Description: We will treat patients with oral encapsulated frozen FMT over 2 days.
Study: NCT00326885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catumaxomab
Description: Catumaxomab is administered intraperitoneally via an indwelling catheter (or port) as a 3-hour infusion 4 times (Days 0, 3, 7, and 10) in ascending doses (10 mcg, 20 mcg, 50 mcg, and 150 mcg, respectively).
Study: NCT00460473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study: NCT06776107

Intervention type: OTHER
Intervention: Risk factor present
Description: Demographic, and severity.
Study: NCT00460473

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo